Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026).

Authors

Kosuke Yoshihara, Terumi Tanigawa, Shin Nishio, Hiroyuki Kanao, Yasunori Yoshino, Ayako Mochizuki, Sari Nakao, Tatsuo Kagimura, Hiroshi Tanabe, Hiroaki Kajiyama, Muneaki Shimada, Aikou Okamoto, Takayuki Enomoto

Published in

Journal of gynecologic oncology. Aug 03, 2026. Epub Aug 03, 2026.

Abstract

The primary objective of the study was to evaluate the safety and effectiveness of olaparib maintenance therapy in Japanese patients with platinum-sensitive first-relapsed ovarian cancer. The secondary objective was to survey the treatment given after the olaparib maintenance therapy.
The JGOG3026 study was a nationwide, multicenter historical cohort study across 43 sites. Patients receiving olaparib maintenance therapy after platinum-based chemotherapy between January 2018 and July 2020 were included as modified intention-to-treat (mITT) 1. Those who received any post-olaparib therapy were extracted as mITT2. The primary endpoint was Grade ≥3 adverse event; secondary endpoints included progression-free survival (PFS), the time to first subsequent therapy (TFST), progression-free survival to the second progression (PFS2), and overall survival (OS).
In the mITT1 (n=413), any Grade ≥3 adverse events occurred in 41.6%; anemia was the most common (28.8%). Myelodysplastic syndrome occurred in 1.0% and no acute myeloid leukemia was observed during a mean follow-up of 34.1 months. The 24-month PFS and OS rates were 31.7% and 70.1%, respectively. Median PFS and OS were 12 months (95% confidence interval [CI]=9.9-13) and 39 months (95% CI=33-45). The 24-month TFST and PFS2 rates were 33.3% and 34.3%. In the mITT2 (n=284), chemotherapy after olaparib therapy was used in 97.2%, with an overall response rate of 22.5%.
Olaparib maintenance therapy showed acceptable safety and effectiveness in Japanese clinical practice. Monitoring for secondary hematologic malignancies is needed after the start of olaparib maintenance therapy.

PMID:
42565791
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.